What is Orthofix's annual revenue?

Written by Editorial Team | Last Updated: August 2026

Orthofix Medical Inc. (NASDAQ: OFIX) generates robust annual net revenues scaling in the hundreds of millions of dollars, typically reporting total yearly revenues between $700 million and $750 million. This top-line financial performance is driven by global sales across its core business segments, which include spine fixation products, biologics, bone growth therapies, and advanced limb reconstruction hardware utilized by hospitals and surgical centers worldwide.

Related FAQs

The President and Chief Executive Officer of Orthofix Medical Inc. is Massimo Calafiore, who also serves as a member of the company's Board of Directors.

Clinical studies evaluating non-invasive bone growth stimulators (which utilize pulsed electromagnetic field or low-intensity ultrasound technology to promote healing in non-union fractures or spinal fusions) generally report high clinical success ra...

The "best" bone growth stimulator is determined by a physician's prescription based on the specific type of fracture, non-union status, or spinal fusion site.

The cost of an Orthofix bone growth stimulator (such as their proprietary spine or extremity therapy units) varies depending on insurance contractual agreements, Medicare fee schedules, and whether the device is rented or purchased.

Prescription bone growth stimulators are high-end medical devices, with retail purchase costs or monthly commercial rental fees ranging broadly from $2,000 to over $4,000 per month depending on the specific model and treatment duration required.

Orthofix Inc. previously faced high-profile federal scrutiny and a major whistleblower False Claims Act lawsuit that resulted in a $42 million global criminal and civil resolution with the U.S. Department of Justice.

In orthopedic and medical device contexts, specialized systems carrying similar names are deployed to stimulate bone healing.

Orthofix Medical Inc. maintains a dedicated global workforce comprising approximately 1,300 to 1,600 employees worldwide.

Yes, Orthofix's core medical devices and bone growth therapy systems are FDA approved or cleared for commercial distribution and clinical use in the United States.

The prescribed duration for wearing a non-invasive bone growth stimulator varies significantly based on the specific anatomical location of the fracture, the severity of the non-union or spinal fusion, and the attending physician's clinical instructi...

Revo Health operates as a prominent management services organization partnering with specialized healthcare practices like Twin Cities Orthopedics.

Yes, Medicare generally covers bone growth stimulators, but coverage is strictly regulated and contingent upon meeting precise medical necessity criteria.

The financial cost of an Orthofix bone growth stimulator varies substantially depending on whether the device is rented or purchased, insurance contract terms, and specific Medicare fee schedules.

Bone growth stimulators are generally considered exceptionally safe medical devices with minimal adverse side effects.

Yes, Medicare generally covers non-invasive bone growth stimulators, but authorization is strictly contingent upon meeting precise medical necessity criteria.

Orthofix Medical Inc.

Clinical and scientific evidence demonstrates that Orthofix's medical devices and orthopedic systems achieve high rates of clinical efficacy when utilized according to strict manufacturer guidelines and physician instructions.

When discussing medical devices or orthopedic care frameworks, "Safix" (or similar variant terminology associated with casting, bandaging, or stabilization products) typically presents minimal localized risks.

Orthofix Medical Inc. is recognized as an established global medical technology enterprise dedicated to advancing spine and orthopedic care solutions.

Orthofix Medical Inc.

The out-of-pocket rental cost for a prescription bone growth stimulator varies significantly depending on health insurance coverage, Medicare provider fee schedules, and specific device models.

Supporting bone fracture healing and overall skeletal health through nutrition requires adequate intake of calcium, protein, and essential micronutrients.

The Ofix 200 Tablet is a prescription fluoroquinolone antibiotic containing 200mg of ofloxacin as its active pharmaceutical ingredient.

When referring to pharmaceutical products like the OFIX tablet (which contains the fluoroquinolone antibiotic ofloxacin), potential side effects can include gastrointestinal discomfort such as nausea, mild diarrhea, abdominal cramps, headaches, dizzi...

The global orthopedic and medical device market features several massive multinational corporations competing for top market share.